NorthStar Medical Radioisotopes has signed a long-term supply agreement with Clovis Oncology for NorthStar's actinium-225 (Ac-225) therapeutic radioisotope.
Under the terms of the deal, NorthStar will provide Clovis with its no-carrier-added Ac-225. Clovis will use Ac-255 to radiolabel its peptide-targeted radionuclide therapeutic candidate, FAP-2286, which is in development and targets fibroblast activation protein (FAP).
